Escherichia coli (E. coli) infections is a disease caused by coming into contact with the stool or feces, of animals or humans. The symptoms associated with the disease include diarrhoea, stomach cramps, nausea and vomiting. The disease in its chronic phase can be diagnosed by observing the symptoms such as pale skin, fever, weakness and bruising. The risk factors associated with the disease include weakened immune system, low stomach acid levels and certain food items including unpasteurized milk or juices and undercooked meat. Arsanis, Inc. is in the process of developing ASN200 for the treatment of E. coli infections. The drug candidate is the being developed as a monoclonal antibody targeting multi-drug resistant E. coli. Some of the companies having a pipeline of E. coli infections include Napo Pharmaceuticals, Inc., and Syntiron LLC.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.